GSK announces LATITUDE phase III interim trial demonstrates ‘superior efficacy’

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi Limited as shareholders, announced results from an interim analysis of the LATITUDE phase III trial, indicating their long-acting injectable antiretroviral treatment for HIV, Cabenuva, or cabotegravir + rilpivirine, demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges. The LATITUDE study is ongoing across 31 sites in the U.S. including Puerto Rico, implemented through Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Once enrolled, participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression. Last week, the DSMB performed a planned interim review. The DSMB recommended that all eligible participants should be offered long-acting injectable cabotegravir + rilpivirine.